By then, the
2010 South African clinical guidelines were aligned with the
WHO guidelines in terms of provision for expanded ARV
regimes, including highly active ARV therapy for mothers, or
nevirapine prophylaxis for infants for the duration of breastfeeding
(up to 12 months of infant age;